Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPTEM for recurrent or refractory MGMT-methylated small cell lung cancer
ChiCTR-OIC-17012216Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Aug 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide and capecitabine in small cell lung cancer (SCLC), sponsored by Chinese PLA General Hospital. Primary endpoints: Objective response rate and Progression-free survival. Started Aug 2017; status: recruiting.
02
Drugs
temozolomidecapecitabine
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR-OIC-17012216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-17012216.